7月2022： Emergen Research が実施した最新の調査によると、CAR T 細胞療法の世界市場は 1.29 年に 2021 億 24.9 万米ドルの規模に達し、予測期間中に XNUMX% の収益 CAGR を記録すると予想されています。 世界中でのがんの発生率の増加とがんによる死亡率の増加が、予測期間中の世界のCAR-T細胞療法市場の収益成長の主な推進要因になると予想されます。 猛烈なペースでの臨床試験活動の拡大、合併・買収の急増、新規株式公開の魅力はすべて、世界のCAR-T細胞療法市場の収益成長に貢献している要因です。
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global CART細胞療法 market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the CART細胞療法 market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
レポートからの追加の重要な調査結果は、
2021年、びまん性大細胞型B細胞のセグメント リンパ腫 was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with キメラ抗原受容体T細胞療法, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell 非ホジキンリンパ腫 who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
現在市場で活動している主要企業は、企業プロファイル、製品ポートフォリオ、拡張戦略、および戦略的提携と同様に、このレポートでさらに調査されます。 これらのタイプの提携の例としては、M＆A、コラボレーション、合弁事業などがあります。 これに加えて、それは会社の業績と財政状態についてのハイライト、ならびに会社の市場リーチとグローバルな位置についての洞察を提供します。
世界のCART-CellTherapy市場で紹介されている企業：
Novartis AG、Pfizer Inc.、CARsgen Therapeutics Co.、Ltd、第一三共株式会社、Bristol-Myers Squibb Company、Astellas Pharma Inc.、BioNTech SE、Biocad、F。Hoffmann-La Roche Ltd.、およびEli Lilly and Company 。
世界のCART-CellTherapy市場レポートの詳細については以下をご覧ください。 https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
